News

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...
The Pharma Letter20h
New data for nusinersen underscore Biogen’s commitment to SMA
US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...
Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...
Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy
New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...
Medindia on MSN2h
Aasmika’s Fight Against Time: How India United to Save One Life
Baby Aasmika with SMA Type 1 received Zolgensma, the world’s most expensive gene therapy, thanks to India's largest-ever ...